PuSH - Publikationsserver des Helmholtz Zentrums München

32 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Clemmensen, C. et al.: Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases. Nat. Rev. Endocrinol. 15, 90-104 (2019)
2.
Jall, S. et al.: Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice. Mol. Metab. 23, 75-81 (2019)
3.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes. Nat. Commun. 9:4304 (2018)
4.
Clemmensen, C. et al.: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes (vol 9, 4304, 2018). Nat. Commun. 9:4975 (2018)
5.
Kleinert, M. et al.: Animal models of obesity and diabetes mellitus. Nat. Rev. Endocrinol. 14, 140-162 (2018)
6.
Kleinert, M. et al.: Time-resolved hypothalamic open flow micro-perfusion reveals normal leptin transport across the blood-brain barrier in leptin resistant mice. Mol. Metab. 13, 77-82 (2018)
7.
Müller, T.D. ; Clemmensen, C. ; Finan, B. ; DiMarchi, R.D.* & Tschöp, M.H.: Anti-obesity therapy: From rainbow pills to polyagonists. Pharmacol. Rev. 70, 712-746 (2018)
8.
Pfuhlmann, K. et al.: Celastrol-induced weight loss is driven by hypophagia and independent from UCP1. Diabetes 67, 2456-2465 (2018)
9.
Renner, S.* et al.: Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs. Mol. Metab., accepted (2018)
10.
Clemmensen, C. ; Jørgensen, C.V.* ; Smajilovic, S.* & Bräuner-Osborne, H.*: Robust GLP-1 secretion by basic L-amino acids does not require the GPRC6A receptor. Diabetes Obes. Metab. 19, 599-603 (2017)
11.
Clemmensen, C. et al.: Gut-brain cross-talk in metabolic control. Cell 168, 758-774 (2017)
12.
Fischer, K. et al.: Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis. Nat. Med. 23, 623-630 (2017)
13.
Jall, S. et al.: Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol. Metab. 6, 440-446 (2017)
14.
Kleinert, M. et al.: Emerging poly-agonists for obesity and type 2 diabetes. Obesity 25, 1647-1649 (2017)
15.
Müller, T.D. ; Finan, B. ; Clemmensen, C. ; DiMarchi, R.D. & Tschöp, M.H.: The new biology and pharmacology of glucagon. Physiol. Rev. 97, 721-766 (2017)
16.
Quarta, C. et al.: Molecular integration of incretin and glucocorticoid action reverses immunometabolic dysfunction and obesity. Cell Metab. 26, 620-632.e6 (2017)
17.
Sánchez-Garrido, M.A. et al.: GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60, 1851–1861 (2017)
18.
Clemmensen, C. ; Müller, T.D. ; Finan, B. ; Tschöp, M.H. & DiMarchi, R.*: Current and emerging treatment options in diabetes care. Handb. Exp. Pharmacol. 233, 437-459 (2016)
19.
de Angelis, M. et al.: Determination of thyroid hormones in mouse tissues by isotope-dilution microflow liquid chromatography-mass spectrometry method. J. Chromatogr. B 1033-1034, 413-420 (2016)
20.
Finan, B. ; Müller, T.D. ; Clemmensen, C. ; Perez-Tilve, D.* & Tschöp, M.H.: Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol. Med. 22, 359-376 (2016)